Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib DDI Study with Metformin, Digoxin, and Rosuvastatin in Advanced Solid Tumors
NCT05828303Phase 1Withdrawn
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of repotrectinib in solid tumor (advanced stage) and metastatic solid tumor, sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Area under plasma-concentration time curve and Maximum Observed Plasma Concentration. Planned start Nov 2024; status: withdrawn.
02
Drugs
repotrectinib
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT05828303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828303.